Narrative Review of Management Strategies and Risk Mitigation for Gastrointestinal Bleeding in Atrial Fibrillation Patients Receiving Warfarin

Abstract

A globally prevalent cardiac arrhythmia, atrial fibrillation (AF) greatly increases the risk of thromboembolic events, making effective anticoagulation necessary. The mainstay of this treatment has long been the vitamin K antagonist warfarin. However, there are significant management challenges due to its limited therapeutic index, intricate pharmacokinetics, and multiple interactions, with gastrointestinal bleeding (GIB) emerging as a serious and potentially fatal complication. The epidemiology, risk factors, mechanisms, and management approaches for GIB in AF patients taking warfarin are summarized in this review. It emphasizes how crucial it is to conduct individualized risk assessments using validated scores, monitor anticoagulation closely, and strategically combine advanced endoscopic procedures with direct oral anticoagulants (DOACs). Increased monitoring and patient education are necessary because of the high early incidence of GIB and the inherent lability of warfarin's anticoagulant effect. Furthermore, accurate clinical differentiation is necessary due to the complex risk profiles of different medications, such as fibrates versus statins. The report highlights the need for a multidisciplinary approach to care, especially in complex situations such as the resumption of post-GIB anticoagulation. It also identifies new endoscopic tools, pharmacogenomics, and artificial intelligence as promising directions for future developments in safer and more individualized patient outcomes.

Keywords

atrial fibrillation gastrointestinal bleeding warfarin anticoagulation management direct oral anticoagulants (DOACs)

Introduction

One of the most common cardiac arrhythmias in the world, atrial fibrillation (AF) significantly increases the risk of thromboembolic events.¹ Over 43 million people worldwide are impacted by its rising incidence, which is expected to reach an age-standardized incidence rate of 54.89 per 100,000 in 2035.² About 10.55 million adults in the US alone suffer from AF, a disorder that is linked to markedly higher risks of stroke, heart failure, myocardial infarction, dementia, chronic kidney disease, and death.³ A growing number of patients needing anticoagulation is directly correlated with the rising prevalence of AF worldwide.^3,4 The public health importance of the inherent difficulties with warfarin therapy and the GIB risk that goes along with it is greatly increased by this demographic shift.⁵ An increasing clinical burden that calls for improved management techniques is highlighted by the fact that a larger AF patient population invariably results in a higher absolute number of GIB events and related complications.^5,6

Warfarin, a vitamin K antagonist (VKA), has been the mainstay of anticoagulation treatment for patients with AF for many years.³ Warfarin therapy is complicated even though it has been shown to be effective in preventing strokes. Its management is particularly difficult due to its limited therapeutic index, the need for frequent laboratory monitoring, and its vulnerability to interactions with a wide range of pharmacologic and dietary agents.^7–9

Gastrointestinal bleeding (GIB) is one of the most concerning and potentially fatal side effects of anticoagulation treatment, particularly when using warfarin.^4,10 With a notable propensity for older patients and those with several comorbidities, GIB plays a significant role in the high mortality rates among AF patients.^11,12 A comprehensive understanding and proactive approach to the risks and management strategies associated with GIB are necessary to optimize patient outcomes in this susceptible group.¹³

In addition to a current viewpoint on pharmacogenomics for customized warfarin dosage, this thorough review attempts to compile the most recent data on new therapeutic approaches, such as targeted direct oral anticoagulant (DOAC) reversal drugs and sophisticated endoscopic procedures. It further highlights a multidisciplinary approach to striking a balance between bleeding risks and effective stroke prevention, with a particular emphasis on the interaction of advanced age and multiple comorbidities. It provides a forward-looking synthesis of current best practices and future research directions.

Methodology

This Study presents a narrative review, chosen to provide a broad and comprehensive overview of the current understanding, key challenges, and emerging advancements related to gastrointestinal bleeding in atrial fibrillation patients on warfarin. This approach allows for the synthesis of diverse evidence from various study types to guide clinical practice and identify future research directions.

Search Strategy

A comprehensive literature search was conducted across electronic databases including PubMed, Embase, Scopus, and Web of Science. The search utilized a combination of keywords and Medical Subject Headings (MeSH) terms such as “Atrial Fibrillation,” “Warfarin,” “Gastrointestinal Bleeding,” “Anticoagulation,” “Risk Management,” “Direct Oral Anticoagulants,” “DOACs,” “Pharmacogenomics,” “Endoscopy,” and “Reversal Agents”. The search was limited to English-language articles published up to May 2024. Additionally, relevant clinical guidelines from major cardiology and gastroenterology societies, and reference lists of identified key articles, were reviewed to ensure comprehensive coverage.

Inclusion and Exclusion Criteria

Articles considered for inclusion encompassed original research studies (eg, clinical trials, cohort studies), systematic reviews, meta-analyses, and clinical guidelines directly relevant to the epidemiology, risk factors, mechanisms, diagnosis, management, prevention, and emerging therapies for GIB in AF patients on warfarin. While narrative reviews are flexible, efforts were made to prioritize pivotal and seminal papers, alongside the most recent and high-impact research. Case reports, editorials, and letters to the editor were generally excluded unless they provided unique, critical insights not available in other formats.

Data Extraction and Synthesis

Information from selected articles was extracted and synthesized thematically. Key findings, methodologies, strengths, and limitations of included studies were critically appraised. The synthesis aimed to identify areas of consensus, controversies, existing knowledge gaps, and promising avenues for future research, providing an expert opinion on the accumulated evidence.

Strength and Limitations of the Review Process

This narrative review has several strengths. A comprehensive search strategy across four major databases, guided by MeSH terms and keyword combinations, allowed inclusion of diverse evidence types and multidisciplinary perspectives. We prioritized high-impact original studies, systematic reviews, and guideline-based evidence to provide a clinically relevant synthesis. However, as a narrative (rather than systematic) review, we did not follow a registered protocol and did not perform quantitative synthesis (eg, meta-analysis). Consequently, some relevant studies may have been missed, and study selection inevitably reflects the authors’ judgment. These features limit reproducibility and preclude formal statistical comparison across interventions or risk factors, but were chosen to enable a broad, interpretive overview of this complex topic.

Epidemiology and Risk Factors for Gastrointestinal Bleeding

Epidemiology of GI Bleeding in Warfarin Users

The incidence of gastrointestinal bleeding in patients on warfarin therapy varies greatly, ranging from 0% to 67%, with an average of 3%.¹⁴ About 5% and 1% of cases, respectively, are more severe, resulting in hemorrhages that are potentially fatal or life-threatening.¹⁴ VKA-related GIB can have a 30-day mortality rate of up to 15.5%, which is mostly determined by the patient's underlying comorbidities rather than just the anticoagulant.^4,15 GIB significantly increases hospitalization rates and medical expenses.^13,16 A significant percentage of GIB episodes—33.3% in the first month and 61.1% in the first year—occur early in the anticoagulation course. Within the first 30 days of starting warfarin, the rate of hospitalization for bleeding peaked at 6.5% per person-year. This high early incidence of GIB attracts close consideration to a crucial time right after starting warfarin, during which patient education and closer monitoring are crucial. This “early peak” implies that preventing serious, potentially lethal complications from warfarin depends heavily on the first stage of dosing and patient acclimatization to its complexities. This time frame is especially susceptible to over-anticoagulation due to the patient's adjustment to the medication and the intrinsic instability of the International Normalized Ratio (INR) during the first dose titration. To prevent these crucial early events, it is important to prioritize risk mitigation strategies in the first few months of therapy. This approach includes careful monitoring, thorough patient education, and possibly more individualized initial dosing algorithms.¹⁷

Risk Factors

Several factors contribute to an elevated risk of GIB in warfarin users, with some carrying a higher risk than others. These can be broadly categorized into patient-related, dietary and social, and drug-drug related factors (Table 1).

Table 1.

Risk Factors for GIB in Warfarin Users.

Category	Risk Factors	Notes
Patient-Related Factors	− Age >80 years − Obesity (>120 kg) − Chronic Kidney Disease (CKD) − Liver Disease − H. pylori Infection − COPD − Sleep Apnea	Elderly patients have a significantly higher risk CKD patients, especially those on dialysis, face elevated bleeding risks
Dietary & Social Factors	− Vitamin K-rich foods (eg, kale, spinach) − Alcohol − Tobacco	Inconsistent vitamin K intake affects warfarin stability Alcohol and tobacco increase bleeding risks
Drug Interactions	− Antihyperlipidemics (Statins, Fibrates) − CYP450 enzyme inhibitors (eg, some antibiotics, antifungals) − Antiplatelet drugs	Drug-drug interactions can enhance warfarin's anticoagulant effects, increasing bleeding risk
Protective Factor	− Proton Pump Inhibitor (PPI) Use	PPI co-therapy reduces GIB risk in warfarin users

Patient-Related Factors

Elderly patients exhibit more complications, including GIB, especially when taking warfarin.⁴ Advanced age is consistently recognized as a significant risk factor. Although some research links GIB risk to people over 65, other research indicates that this relationship is stronger in people over 80 or 85. A higher risk of GIB has also been associated with obesity, specifically a weight of more than 120 kg or a BMI of more than 30 kg/m2. Major GIB rates for warfarin users were 14.0% at one year and 16.2% at five years, according to a study comparing DOACs and warfarin in patients with a BMI of 50 kg/m2 or higher.¹⁸

Another important contributing factor is chronic kidney disease (CKD), where 2% of patients experience GIB, particularly those who are hospitalized and have a significantly higher risk of bleeding.¹⁹ Dialysis patients also have a higher long-term incidence of GIB.^20,21 Other patient-related factors linked to GIB include liver failure and cirrhosis. Although there are concerns about increased bleeding risk, particularly in patients with more advanced cirrhosis (Child-Pugh B or C), and the challenge of managing INR, some studies indicate that warfarin can lower the risk of stroke in cirrhotic patients with AF, especially those with less severe liver disease (Child-Pugh A). Newer anticoagulants (DOACs) appear to have a better safety profile regarding bleeding compared to warfarin in this population.^22,23

H. pylori infection, a history of sleep apnea, and chronic obstructive pulmonary disease (COPD) are further patient-related factors associated with GIB.¹⁸ A history of sleep apnea is identified as a probable risk factor for anticoagulant-associated GIB. Similarly, a history of COPD was identified as an independent predictor of major bleeding events in AF patients on anticoagulation.¹⁸

Conversely, the use of proton pump inhibitors (PPIs) has been shown to significantly lower the risk of GIB in warfarin-treated patients, acting as a protective factor.²⁴ Evidence for patients taking warfarin alone, however, is mixed. Some studies attribute the association to indication-specific confounding, in which PPIs are administered to patients who are sicker or taking other GI-toxic medications.²⁵ The observed intricacy of PPI use emphasizes how complex real-world clinical situations are, where polypharmacy and several comorbidities frequently coexist. Some studies attribute the association to confounding by indication, while others propose a direct protective effect. Instead of prescribing a proton pump inhibitor routinely to all warfarin-treated patients, this suggests that prophylactic PPI use should be carefully considered, giving priority to those with additional GI risk factors, such as a history of GIB or concurrent NSAID or antiplatelet use. According to this nuanced understanding, PPIs shouldn't be randomly prescribed to all warfarin users in order to prevent GIB. In order to prevent needless polypharmacy and possible PPI side effects, a targeted strategy that co-prescribes PPIs for patients with particular, identifiable GI risk factors would be more appropriate and supported by evidence. For risk management, patients with a history of GIB receiving warfarin therapy may be advised to take acid suppressants.^21,26,27

Dietary and Social Factors

Although there isn't a specific “warfarin diet,” some foods and beverages can affect the medication's functions. Vitamin K-rich foods, such as spinach, kale, green tea, and Brussels sprouts, can reduce the anticoagulant effects of warfarin, so regular consumption is necessary.^28,29 Clinical recommendations have evolved to place more emphasis on “consistent intake” of foods high in vitamin K than “avoidance.” This change suggests a departure from strict dietary recommendations, which may cause patients to become confused and result in an unstable INR, in favor of a more pragmatic strategy that teaches patients how to maintain INR stability through dietary consistency. Additionally, this subtly emphasizes how crucial patient education is to warfarin management. This proactive educational approach can empower patients to better manage their therapy and reduce the risk of diet-induced INR fluctuations and subsequent bleeding events. Cranberry juice and alcohol should be consumed in moderation due to their potential to potentiate warfarin's anticoagulant effects, thereby increasing bleeding risk. Social factors such as alcohol and tobacco consumption substantially raise GIB risk.^9,30,31 Other social elements, including poor housing conditions and non-adherence to medical treatments, have also been identified as potential contributors.¹⁸

Drug-Drug Interactions (DDIs)

Due to its narrow therapeutic index, warfarin is particularly vulnerable to drug-drug interactions (DDIs), which can result in excessive anticoagulation and a higher risk of bleeding.⁹ Warfarin levels can rise as a result of the inhibition of cytochrome P450 enzymes (CYP2C9, CYP3A, and CYP1A2), which are essential for warfarin metabolism, by some drugs, especially some anti-hyperlipidemics.^32–34 Furthermore, other medications can displace warfarin due to its strong plasma protein binding (about 99%), which raises its free concentration and amplifies its anticoagulant effect.³⁵

When taken with warfarin, medications like fibrates (such as gemfibrozil and fenofibrate) may also have inherent antiplatelet or anticoagulant traits, which increases the risk of bleeding. However, statins and warfarin typically do not increase the risk of GIB/ICH.³⁶ The complex results about fibrates and statins show that not all anti-hyperlipidemic medications have the same risk of bleeding when taken with warfarin. Even though some statins have potential antiplatelet/anticoagulant effects or alter CYP450 enzymes, fibrates are consistently associated with elevated GIB/ICH. This suggests that instead of classifying all anti-hyperlipidemic medications as high-risk, clinicians should distinguish between these drug classes when determining DDI risk with warfarin. This offers practical clinical advice: although caution is always necessary in the setting of polypharmacy, clinicians should be particularly alert to fibrates as the anti-hyperlipidemic class most consistently associated with increased bleeding risk when combined with warfarin, whereas most statins can often be continued safely. This distinction enables more accurate risk assessment and may prevent unnecessary statin discontinuation or dose reduction in otherwise stable patients. These interactions emphasize the importance of close observation, particularly in older adults who often take several medications, since polypharmacy can lead to serious side effects like GIB and intracranial hemorrhage.^32,37,38 These possible risk factors for GIB in patients receiving warfarin treatment are succinctly summarized in Table 1.

Bleeding Risk Scores in AF Patients on Anticoagulation

In clinical practice, a number of validated bleeding risk scores are frequently used to stratify the risk of major bleeding in AF patients receiving anticoagulation, such as warfarin, in addition to individual risk factors.³⁹ These scores combine a number of clinical and patient-specific variables to produce a quantitative evaluation of bleeding risk, which facilitates collaborative decision-making about anticoagulation treatment.

HAS-BLED: The HAS-BLED score (Hypertension, Abnormal renal/liver function, Stroke, prior major Bleeding or predisposition, Labile INR, Elderly age >65, Drugs/alcohol) provides a simple bedside estimate of major-bleeding risk in warfarin-treated AF. Higher scores indicate greater risk (eg, 0 points ≈ 0.9-1.13% annual major bleeding).⁴⁰ Crucially, bleeding scores should not be used as an absolute cut-off to withhold anticoagulation; rather, they identify patients who need risk-factor modification and closer follow-up while anticoagulation decisions remain individualized against thromboembolic risk..⁴⁰

ORBIT: Another validated tool for evaluating bleeding risk in AF patients taking oral anticoagulants is the ORBIT Score (Older age, Reduced hemoglobin/hematocrit or prior bleeding, Hypertension, Impaired Renal Function, Treatment with Antiplatelet Agents), particularly informative when baseline anemia, prior bleeding, or concomitant antiplatelet therapy are central concerns; a higher score supports proactive correction of anemia, reassessment of antiplatelet necessity, and vigilance for occult GI sources before and during anticoagulation.^41,42

ATRIA: Moreover, predictive values for bleeding risk are also provided by the ATRIA Score (Anemia, previous bleeding, Renal disease, Hypertension, Age) derived from large community-based populations and similarly offers predictive values for major bleeding.³⁹ According to studies, bleeding risk can be accurately predicted by scores like ORBIT and HAS-BLED. Close observation is regarded as a safe treatment strategy, especially for patients with high scores.⁴⁰ These tools facilitate a more systematic and individualized assessment of bleeding risk, allowing clinicians to balance stroke prevention with bleeding complications effectively (Table 2).

Table 2.

Common Bleeding Risk Scores in Atrial Fibrillation Patients on Anticoagulation.

Score Name	Key Components/Variables	Predictive Utility for GIB Risk	Notes/Clinical Application
HAS-BLED	Hypertension, Abnormal renal/liver function, Stroke history, Prior major Bleeding, Labile INR, Elderly (>65 years), Drugs/alcohol predisposing to bleeding	Higher score indicates increased major bleeding risk (eg, 0 points: 0.9-1.13% annual risk)	Widely used; should not be an absolute cut-off for withholding anticoagulation; stroke risk often outweighs bleeding risk
ORBIT	Older age, Reduced hemoglobin/hematocrit or prior bleeding, Hypertension, impaired Renal function, Treatment with antiplatelet agents	Validated for assessing bleeding risk in AF patients on oral anticoagulants	Useful for risk stratification alongside clinical judgment
ATRIA	Anemia, previous bleeding, Renal disease, Hypertension, Age	Provides predictive values for bleeding risk	Another tool for comprehensive risk assessment in AF patients

Consistent use of one validated score, coupled with systematic mitigation of modifiable risks, is more important than the specific choice of score. In warfarin-treated patients, HAS-BLED often provides the most actionable levers (eg, labile INR, interacting drugs), while ORBIT or ATRIA can be preferred when anemia or renal dysfunction dominate the bleeding phenotype. Regardless of the tool, a higher score should trigger (i) targeted correction of modifiable factors, (ii) closer INR monitoring and patient education, and (iii) periodic re-scoring after interventions, rather than automatic cessation or denial of anticoagulation.

Mechanisms of GI Bleeding in Warfarin Users

The main way that warfarin works is by competitively blocking the production of vitamin K-dependent clotting factors (II, VII, IX, and X) and vitamin K epoxide reductase (VKOR). Warfarin inhibits VKOR, an enzyme essential for vitamin K activation, which damages the coagulation cascade.⁴³ The synthesis of active clotting factors II, VII, IX, and X, as well as regulatory proteins C and S, is subsequently reduced as a result of this decrease in functional vitamin K levels.^9,34,44

Despite its effectiveness, the complicated pharmacokinetics of warfarin result in a variety of drug-food interactions and patient response variations caused by genetic polymorphisms in the CYP2C9 and VKORC1 genes.^28,45 Warfarin is quickly absorbed; its effects usually start to show up 24 to 72 h later, and its plasma concentration peaks in about 4 h. A complete therapeutic response, however, usually takes five to seven days to manifest. The medication is approximately 99% protein-bound and has a small volume of distribution.⁹

Warfarin's limited therapeutic window and significant inter-patient variability in dose requirements are caused by these factors, especially genetic polymorphisms in CYP2C9 and VKORC1 and a variety of drug and food interactions.⁴⁶ Less than 70% of the time, patients stay within the therapeutic range due to this intrinsic complexity, which frequently causes fluctuations in the International Normalized Ratio (INR).⁴⁷ These pharmacokinetic and pharmacogenomic issues result in periods of supra-therapeutic INR, which directly put patients at risk for mucosal bleeding and worsen bleeding from pre-existing lesions like peptic ulcers or angiodysplasia.^4,48 Given that patients frequently stay within the therapeutic range less than 70% of the time and that periods of supra-therapeutic INR are directly linked to an increased risk of bleeding, managing warfarin presents a significant challenge. This suggests that maintaining consistent anticoagulation is challenging, even with careful monitoring, leaving patients at risk for bleeding. Maintaining ideal anticoagulation is difficult because of the intrinsic lability of INR brought on by the intricate pharmacokinetics, pharmacogenomics, and multiple interactions of warfarin. Bleeding events are directly caused by this lability. This demonstrates that bleeding with warfarin is frequently a result of the pharmacology of the medication itself rather than being exclusively the result of patient non-adherence or physician fault. This highlights the necessity of sophisticated management techniques, like pharmacogenomics-guided dosage and possibly the switch to DOACs, which provide less monitoring load and more predictable pharmacokinetics. The dynamic nature of bleeding risk with warfarin therapy is highlighted by the difficulty in maintaining appropriate anticoagulation, even under strict monitoring.⁴⁹

Clinical Presentation and Diagnosis

To ensure its safety and effectiveness, patients undergoing warfarin therapy need to be closely and consistently monitored. Frequent blood tests are essential for measuring the International Normalized Ratio (INR), which standardizes results across laboratories, and Prothrombin Time (PT).⁵⁰ Depending on their individual medical condition, warfarin patients typically have therapeutic INR goals between 2.0 and 3.0, with a target of 2.5 for the majority of people.⁵¹ The frequency of monitoring is especially important during the first phase of warfarin therapy, when hospitalized patients are advised to have daily INR checks.⁵¹ Assessments are usually performed every four weeks after the patient's INR stabilizes, though this frequency can be changed depending on specific clinical circumstances.^8,52

Hematemesis, defined as blood in the vomit, melena, as dark and tarry stools, and hematochezia, as bright red blood in the stool, are common clinical manifestations of gastrointestinal bleeding in warfarin users.⁵³ Due to blood loss, patients may also show signs of anemia, such as pallor and fatigue.⁵⁴ Patients must be continuously monitored for any clues of bleeding. Prior to starting warfarin therapy, baseline hemoglobin and hematocrit levels should be determined. After that, they should be reassessed every six months. Depending on the patient's clinical presentation and INR results, more laboratory testing might be required.^9,55

To assess the extent of bleeding and direct the promptness of diagnostic and treatment measures, a quick clinical evaluation and preliminary risk assessment are essential at presentation.⁵⁴ Endoscopy is still the gold standard diagnostic procedure for conclusively determining the source of the bleeding. Alternative imaging techniques like CT angiography or tagged red blood cell scintigraphy may be used to locate the bleeding site in hemodynamically unstable patients when prompt endoscopic evaluation may be difficult or delayed.^56–58 An important clinical pathway is highlighted by the recommendation for “rapid clinical assessment and initial risk stratification” that is immediately followed by the reference to endoscopy as the “gold standard” and alternative imaging for patients who are unstable. This suggests a tiered diagnostic strategy in which the type and urgency of imaging are determined by patient stability, guaranteeing that a conclusive diagnosis is made effectively without endangering patient safety. This is a dynamic, stability-driven algorithm rather than a linear diagnostic process. Before a potentially risky or time-consuming endoscopy can be performed, if the patient is unstable, immediate stabilization and less invasive, faster imaging modalities are prioritized to localize bleeding. In emergency situations where patient physiology determines the urgency of the diagnosis, this is a reflection of best clinical practice. It emphasizes the value of a clear institutional protocol for managing GIB that combines diagnostic pathways with initial resuscitation, ensuring that the best and safest diagnostic method is selected according to the patient's condition.

Management Strategies

Immediate Management

In order to stabilize the patient and reduce the risk of further bleeding and related complications, immediate management of GIB in patients taking warfarin necessitates a highly coordinated and rapid reaction. Hemodynamic stabilization, immediate anticoagulation reversal, and effective bleeding control are the main goals.^59,60

Hemodynamic Stabilization

Securing the patient's airway is the first crucial step. To avoid aspiration, endotracheal intubation should be considered in severe cases of upper gastrointestinal bleeding that are accompanied by hematemesis or altered consciousness.^59,61 Restoring intravascular volume by starting isotonic crystalloid fluid resuscitation right away (eg, normal saline or lactated Ringer's solution) is the next crucial step.¹⁴ Concurrently, patients with hemodynamic instability or hemoglobin levels below 7–8 g/dL may benefit from packed red blood cell (PRBC) transfusions; the specifics will depend on the patient's overall clinical situation. To direct continued care, it is crucial to continuously monitor laboratory tests (hemoglobin, hematocrit, coagulation profile, and renal function) and vital signs (heart rate, blood pressure, oxygen saturation).^14,59,61

Anticoagulation Reversal

In cases of GIB brought on by an excessive anticoagulant effect, it is critical to quickly reverse the anticoagulation caused by warfarin.⁵⁹ The degree of bleeding and the urgency of the intervention determine which reversal agents are used. In cases of potentially fatal bleeding episodes, prompt reversal is especially important.¹³ The available options are summarized in Table 3.

Table 3.

Description of Reversal Agents.

Agent	Dosing	Onset of action	Advantages	Disadvantages
Vitamin K	IV (1-10 mg) for severe cases; oral (2.5-5 mg) for non-emergencies	6-24 h	Restores clotting factor synthesis	Slow onset, may cause warfarin resistance
4F-PCC (Four-Factor Prothrombin Complex Concentrate)	25–50 IU/kg (max 5000 IU)	Minutes	Rapid and effective reversal	Risk of thrombosis, expensive
FFP (Fresh Frozen Plasma)	10–15 mL/kg	Variable	Rapid and effective reversal	Large volume required, risk of transfusion reactions, slower onset

Endoscopic Interventions

Management of GIB frequently requires various endoscopic therapeutic techniques at that point the diagnosis is established.⁶² The primary methods for achieving hemostasis include injection therapy, thermal coagulation, mechanical therapy, and the use of hemostatic powders.⁵⁵ These techniques provide several choices for effectively managing GIB based on the specific circumstances and lesions discovered.^63,64

Using substances like saline or diluted epinephrine (1:10,000 to 1:20,000), injection therapy produces local tamponade and vasoconstriction. Since thermal coagulation or clipping are more effective than monotherapy, it is frequently used as a supplement to other modalities. In order to cause vascular thrombosis, other sclerosants, like absolute alcohol, can be injected; however, because of the possibility of tissue necrosis, these must be used with great caution. By causing heat-induced tissue damage, thermal coagulation—which can be performed using contact probes or argon plasma coagulation (APC)—achieves hemostasis.⁶⁵ APC employs ionized argon gas for non-contact thermal coagulation, with power settings modified according to tissue thickness in various GI regions, whereas contact probes compress the bleeding vessel during coagulation.⁶⁴

Similar to surgical ligation, mechanical therapy, mostly using endoscopic clips, grasps blood vessels or tissue without causing damage.⁶⁶ This technique is thought to be useful for controlling acute bleeding as well as lowering the rate of rebleeding because it provides instant hemostasis without causing further tissue damage.⁶⁷ By offering larger and stronger mechanical compression, Over-the-Scope Clips (OTSCs), a more recent development, overcome the drawbacks of conventional through-the-scope clips, which have small arms that limit their effectiveness on large vessels.⁶⁸ Because of this, OTSCs are especially helpful for iatrogenic perforations, large vessels, and severe bleeding.⁵⁵

A more recent endoscopic hemostatic technique is the use of hemostatic powders, such as Hemospray (TC-325). It works by establishing a mechanical barrier at the bleeding site, which promotes the formation of a clot right away. Although rebleeding rates can range from 10% to 49%, Hemospray success rates have been between 75% and 100%.⁶⁹ Despite its efficacy, this device only has a short-term impact because the product may disappear in the gastrointestinal tract in as little as 24 h.⁶⁹ In order to manage upper gastrointestinal bleeding associated with peptic ulcers, for instance, gastroenterologists are increasingly using endoscopic suturing devices, which have been made easier to use.⁷⁰

The constant need for better and more effective bleeding control is reflected in the shift from conventional injection therapy to advanced mechanical techniques like OTSCs and hemostatic powders. The choice of endoscopic modality is highly tailored to the source and severity of bleeding, as evidenced by the unique benefits of OTSCs for large vessels and perforations and the transient nature of hemostatic powders. This demonstrates that access to a wide range of tools and endoscopic expertise are essential for the best possible patient outcomes. This development in endoscopic capabilities highlights a fundamental change in GIB management, toward interventions that provide better long-term results and less invasiveness in addition to immediate hemostasis. A more individualized and successful therapeutic approach is made possible by the ability to choose the best tool depending on the particular lesion and patient circumstances.

Risk Mitigation and Preventive Strategies

Anticoagulation Monitoring

In order to avoid complications and maintain a careful balance between preventing stroke and bleeding risk in AF patients taking warfarin, regular monitoring of anticoagulation therapy is essential. In order to minimize thromboembolic events and hemorrhagic complications, the main goal is to keep the INR within the therapeutic range (2.0-3.0), with a target of 2.5 for the majority of patients.⁷¹

To avoid over-anticoagulation, regular INR checks are necessary. Usually, this entails testing the INR on days three and five of treatment, then every two weeks until it stabilizes. After the INR stabilizes, the frequency of monitoring can be progressively decreased to weekly, biweekly, and eventually monthly. However, elderly patients those with liver or kidney impairment, or taking medications that interact with warfarin may require more frequent monitoring (weekly or biweekly). Additionally, keeping the INR within the therapeutic range, one of the most important quality indicators for warfarin management is the Time in Therapeutic Range (TTR). For anticoagulation treatment to be effective, patients should ideally maintain a TTR >70%.^48,71 Consistent INR control is crucial because low TTR values are directly linked to a higher risk of significant bleeding.⁹ Compared to routine office-based monitoring, studies indicate that patient self-testing and self-management of INR can lower the incidence of major bleeding events as well as thrombotic events.⁸ TTR can be improved and complications can be decreased with regular INR checks, patient education, and self-monitoring/management.⁷²

Alternative Anticoagulants (Direct Oral Anticoagulants - DOACs)

For the prevention of stroke in AF, direct oral anticoagulants (DOACs) have become more and more popular substitutes for warfarin. Their widespread use can be attributed to their predictable pharmacokinetics, ease of use, and generally lower risk of major bleeding when compared to warfarin.^51,73 In numerous studies involving AF and other anticoagulant users, DOACs like dabigatran, apixaban, and rivaroxaban have continuously shown lower rates of GI bleeding when compared to warfarin.^74–77

Nonetheless, there are significant distinctions between the DOACs themselves. Significant variations in GIB risk were found in a recent real-world cohort study that included over 3300 new users of warfarin or DOACs. Patients on edoxaban or apixaban had a 26% lower risk of GIB within the DOAC subgroup than those on dabigatran or rivaroxaban.⁷⁸ Warfarin and rivaroxaban were linked to a high risk of GIB, according to another retrospective analysis of almost 3000 hospitalized GIB patients.⁷⁸ According to this analysis, DOACs considerably reduce the rates of bleeding events and all-cause mortality in cirrhotic patients when compared to warfarin.⁷⁵ In conclusion, the evidence clearly favors the use of DOACs as the recommended anticoagulant drugs for patients who are at high risk of gastrointestinal bleeding, especially those who have long-term medical conditions. To completely maximize their use, more research is necessary to assess more precise information about DOAC therapy, particularly in patients with life-threatening conditions and across age groups. Table 4 provides a comparison of DOACs and warfarin.

Table 4.

Comparison of Direct Oral Anticoagulants (DOACs) and Warfarin for GIB Risk and Efficacy in Atrial Fibrillation.

Anticoagulant Type	Mechanism of Action	GIB Risk (relative to warfarin)	Stroke Prevention Efficacy (relative to warfarin)	Availability of Specific Reversal Agents	Key Clinical Advantages	Key Clinical Disadvantages
Warfarin	Vitamin K antagonist; inhibits factors II, VII, IX, X, proteins C & S	Baseline risk; higher than most DOACs	Established efficacy	Vitamin K, 4F-PCC, FFP	Long-standing experience, low cost, INR monitoring allows for dose adjustment	Narrow therapeutic index, frequent monitoring, numerous drug/food interactions, higher GIB risk
Dabigatran	Direct thrombin inhibitor	Generally lower than warfarin; higher than apixaban/edoxaban	Non-inferior/superior	Idarucizumab	No routine monitoring, fewer drug interactions, rapid onset/offset	Renal excretion (requires dose adjustment in CKD), dyspepsia, higher GIB than some DOACs
Rivaroxaban	Direct factor Xa inhibitor	Generally lower than warfarin; higher than apixaban/edoxaban	Non-inferior	Andexanet alfa	Once-daily dosing, no routine monitoring, fewer drug/food interactions	Renal excretion (requires dose adjustment in CKD), higher GIB than some DOACs
Apixaban	Direct factor Xa inhibitor	Generally lower than warfarin; lowest among DOACs for GIB	Non-inferior/superior	Andexanet alfa	Lowest GIB risk among DOACs, dual renal/hepatic excretion (broader applicability), no routine monitoring	Twice-daily dosing, higher cost
Edoxaban	Direct factor Xa inhibitor	Generally lower than warfarin; comparable to apixaban for GIB	Non-inferior	Andexanet alfa	Once-daily dosing, no routine monitoring, fewer drug/food interactions	Requires dose adjustment for renal function, specific weight/creatinine clearance criteria

Initiation of Anticoagulation Post-GIB

A patient's personal risk of recurrent bleeding must be carefully evaluated regarding their continuing risk of thromboembolic events when deciding whether to resume anticoagulation following a gastrointestinal bleeding event. This is a difficult and high-stakes clinical decision.⁷⁹ The evidence currently available supports the default strategy of resuming anticoagulation therapy for GIB survivors, despite the high level of anxiety experienced by clinicians.⁸⁰ Resuming anticoagulation therapy following GIB is linked to a significant decrease in thrombotic events and overall mortality when compared to permanent discontinuation, according to studies and meta-analyses.⁸¹

To balance these risks, the best time to re-initiate is crucial. Research indicates that the best balance between lowering the risk of recurrent bleeding and preventing thromboembolic events and mortality may be achieved by waiting between 14 and 30 days following the index GIB.⁸² A markedly higher incidence of recurrent GIB has been linked to starting warfarin again within 7 days.⁸² The severity and cause of the bleeding, the patient's comorbidities, their underlying thromboembolic risk (eg, high CHA2DS2-VASc score), and their preferences should all be considered in the personalized decision.⁷⁹ Navigating these complexities and improving patient outcomes requires a multidisciplinary approach involving hematologists, cardiologists, and gastroenterologists.

Emerging Therapies and Future Directions

The treatment of GIB in patients on anticoagulation, especially warfarin, is constantly changing due to advancements in therapeutic modalities and technological innovations, which promise better patient outcomes, safety, and efficacy.

Even though DOACs are generally less likely to cause GIB than warfarin, severe bleeding episodes linked to DOACs may still require quick reversal. To meet this need, targeted reversal agents have been created. Dabigatran can be specifically reversed with idarucizumab, and factor Xa inhibitors like rivaroxaban and apixaban can be reversed with andexanet alfa.^83,84 Strong clinical trials and practical safety and efficacy evaluations have substantiated these agents’ quick and efficient hemostasis restoration. The overall safety profile of DOACs is improved by the growing availability and effectiveness of these reversal agents, which may encourage more appropriate patients to switch from warfarin to DOACs.⁶⁰

By discovering genetic variations affecting the metabolism of warfarin, particularly those in the CYP2C9 and VKORC1 genes, pharmacogenomic insights have transformed the appropriate management of anticoagulation. A considerable amount of the inter-individual variability in warfarin dose requirements can be explained by these genetic variations.^9,84 An optimal stable daily dose of warfarin is predicted by personalized dosing algorithms, like those offered by the International Warfarin Pharmacogenetics Consortium (eg, on PharmGKB and warfarindosing.org), which combine genetic data with clinical factors (eg, age, weight, interacting drugs). People who inherit copies of CYP2C9 2 or 3 or certain VKORC1 haplotypes, for example, frequently need lower doses of warfarin and are more likely to bleed.^84,85 When genetic information is available, genotype-dosing tables are also included on the label of the FDA-approved warfarin product to help guide initial dosing.⁸⁶ Compared to empirical dosing, clinical trials have shown that genotype-guided dosing can result in more stable INR control and possibly lower bleeding risk. Improved patient outcomes may result from using such tailored strategies to improve warfarin's overall safety profile.⁸⁵ In order to increase safety and further customize treatment, future research will probably improve these pharmacogenomic techniques and apply them to other anticoagulants, such as DOACs.

The treatment of severe GIB has advanced quickly thanks to recent advancements in endoscopic hemostatic modalities. Hemostatic sprays, over-the-scope clips, and suturing tools are examples of innovations.⁶⁹ Compared to earlier techniques like epinephrine injection or thermal probes, these newly developed instruments improve precise bleeding control, frequently avoiding the need for surgical intervention and producing better clinical results.⁶⁹ Additionally, machine learning (ML) and artificial intelligence (AI) are showing promise as risk stratification modalities in GIB. Although banding ligation and glue injection are still the preferred methods for treating variceal hemorrhage, endoscopic ultrasound-guided therapy is becoming more popular because it provides greater precision.^67,87,88

In critical care settings, where patients frequently present with additional risk factors, a multidisciplinary approach is essential to managing GIB. Because it contributes to high morbidity and mortality, GIB is still a major concern in the intensive care unit.⁸⁹ This calls for a successful resuscitation and intervention plan to increase critically ill patients’ chances of survival and care quality. The choice to resume anticoagulation following a bleeding event is a complicated one that necessitates careful evaluation of a number of variables, including the patient's personal preferences, the extent of the bleeding, and their underlying stroke risk. Navigating these difficult clinical situations requires multidisciplinary input.⁹⁰

Discussion

A persistent clinical challenge in the treatment of atrial fibrillation patients who need anticoagulation involves establishing a careful balance between the substantial risk of gastrointestinal bleeding and the effective prevention of stroke. From its epidemiology and underlying mechanisms to its current management and potential therapeutic methods, this review has synthesized the available data to shed light on the complex nature of GIB in warfarin users.

The results highlight the fact that GIB is a frequent and potentially fatal side effect in patients with AF receiving warfarin, and that patient comorbidities have a significant impact on incidence rates and mortality. A highly customized patient evaluation is required because key risk factors like advanced age, chronic kidney disease, and complicated drug-drug interactions are consistently found to be significant contributors. Recognizing that clinicians use validated bleeding risk scores, such as HAS-BLED, ORBIT, and ATRIA, to integrate these risks into a quantitative assessment that provides clinical decision-making and patient counseling, enriches the discussion of these individual factors. Optimizing the risk-benefit profile of anticoagulation requires a methodical approach to risk stratification.

Understanding GIB susceptibility requires an understanding of the inherent complexity of warfarin's pharmacokinetics and pharmacogenomics. The instability of the International Normalized Ratio (INR) is directly caused by the variation in the CYP2C9 and VKORC1 genes as well as a variety of food and medication interactions. Bleeding events are directly caused by this INR lability, which frequently leaves patients in the therapeutic range for less than 70% of the time. This emphasizes that consistent anticoagulation and a reduction in bleeding risk require careful monitoring, ideally including Time in Therapeutic Range (TTR), which is a crucial component of effective warfarin management.

The development of direct oral anticoagulants (DOACs) has marked significant advances in the treatment of anticoagulation. This review highlights significant variations in GIB risk among individual DOACs while also confirming their generally lower risk when compared to warfarin. Treatment selection requires this nuanced understanding, particularly in high-risk populations. Additionally, the development of hemostatic powders and over-the-scope clips provides more accurate and efficient tools for managing acute bleeding episodes, improving patient outcomes and frequently avoiding the need for more invasive surgical procedures.

The choice to resume anticoagulation after a GIB event is a crucial and frequently stressful clinical issue. Resuming anticoagulation is strongly supported by the evidence for the majority of GIB survivors, as it significantly lowers the risk of subsequent thromboembolic events and overall mortality when compared to permanent discontinuation. Re-initiation must be timed carefully, though, as the window between 14 and 30 days after the bleeding provides the best balance between reducing the risk of thrombosis and preventing further bleeding. This difficult choice emphasizes the need for a multidisciplinary strategy that incorporates findings from hematologists, cardiologists, and gastroenterologists.

Despite having a broad scope, this narrative review has some inherent limitations. It may not contain all pertinent literature on the subject because it lacks a systematic search strategy and quantitative synthesis, like a meta-analysis. As such, the selection of articles may naturally reflect the authors’ viewpoints even though it aims to give a comprehensive and interpretive overview. To offer a more conclusive quantitative synthesis of particular interventions or risk factors, future systematic reviews and meta-analyses would be beneficial.

This review has significant clinical implications. It emphasizes the necessity for physicians to manage anticoagulation in a proactive, patient-centered manner by incorporating thorough risk assessment instruments, ongoing observation, and individualized treatment regimens. In order to better predict and prevent GIB, future research should focus on improving risk stratification techniques, especially through the use of artificial intelligence and machine learning. The ability to customize treatments to each patient's unique genetic profile and maximize safety and efficacy through further improvement of pharmacogenomic dosing algorithms for warfarin and possibly DOACs is extremely promising. Clinical recommendations will be further improved and patient care will be enhanced by ongoing research into the relative efficacy of more recent endoscopic procedures and the best practices for resuming anticoagulation.

Conclusion

In conclusion, a careful and individualized approach is required to manage atrial fibrillation patients on anticoagulation in a way that balances the significant risk of gastrointestinal bleeding along with prevention of stroke. Warfarin is still an essential treatment, but its complications highlight how crucial it is to perform a personalized risk assessment, closely monitoring, and properly combine direct oral anticoagulants with advanced endoscopic procedures. Improving risk stratification, using pharmacogenomics to create customized treatments, and encouraging cooperative multidisciplinary care must be the top priorities of future efforts. Improving results for this susceptible patient group ultimately depends on well-informed, patient-centered decision-making as well as the ongoing incorporation of the latest innovations and technologies and research findings.

Footnotes

Acknowledgements

None.

ORCID iD

Ramtin Pourahmad

Ethical Compliance

Not applicable.

Author Contributions

A.S.S conceptualized the study, conducted the literature search, designed the tables, drafted the initial manuscript, and performed critical revisions. A.EN carried out the literature review, extracted data for table compilation, and drafted sections on the theoretical framework. M.H developed the overall methodology, selected and curated studies for inclusion in the tables, and edited the content. M.K performed thematic analysis, structured and formatted the tables, and prepared visual elements as needed. S.H.B managed references and formatted the tables according to journal guidelines. K.R interpreted the clinical implications, carried out writing-review and editing tasks. R.A reviewed the final manuscript and provided scientific supervision and guidance and gave final approval of the manuscript. R.P oversaw project administration and conceptualization, supervised all stages of the work, handled correspondence with the journal, and coordinated preparation of the final manuscript.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Access Statement

Not applicable.

References

Kirchhof

Benussi

Kotecha

, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. doi:10.1093/eurheartj/ehw210

Kornej

Börschel

Benjamin

Schnabel

. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020;127(1):4-20. doi:10.1161/CIRCRESAHA.120.316340

Carnicelli

Hong

Connolly

, et al. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022;145(4):242-255. doi:10.1161/CIRCULATIONAHA.121.056355

Scridon

Balan

. Challenges of anticoagulant therapy in atrial fibrillation-focus on gastrointestinal bleeding. Int J Mol Sci. 2023;24(8):6879.

Treewaree

Lip

GYH

. An Updated Global Perspective of Atrial Fibrillation: Trends, Risk Factors, and Socioeconomic Disparities. CJC Open. 2025;7(3):259-261. doi:10.1016/j.cjco.2024.12.003

Chung

Evans

Benjamin

Helm

. Atrial Fibrillation: A Review. Jama. 2025;333(4):329-342. doi:10.1001/jama.2024.22451

Holbrook

Schulman

Witt

, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S-ee84S. doi:10.1378/chest.11-2295

Tideman

Tirimacco

St John

Roberts

. How to manage warfarin therapy. Aust Prescr. 2022;38(2):44-48. doi:10.18773/austprescr.2015.016

Patel

Singh

Preuss

Patel

. Warfarin. StatPearls [Internet]: StatPearls Publishing; 2024.

10.

Ingason

Hreinsson

Björnsson

. Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known. Drug Saf. 2022;45(12):1449-1456. doi:10.1007/s40264-022-01243-7

11.

Sainbayar

Ibrahim

Noh

, et al. Gastrointestinal bleed mortality disparities in patients with atrial fibrillation: A cross-sectional analysis 1999–2020. J Arrhythm. 2025;41(1):e13223. doi:10.1002/joa3.13223

12.

Kooistra

Calf

Piersma-Wichers

, et al. Risk of bleeding and thrombosis in patients 70 years or older using vitamin K antagonists. JAMA Intern Med. 2016;176(8):1176-1183. doi:10.1001/jamainternmed.2016.3057

13.

Ullah

Arif

Khan

, et al. Comparative Outcomes of Warfarin vs. Direct Oral Anticoagulants (DOACs) in Anticoagulant-Related Gastrointestinal Bleeding: A Single-Center Study. Cureus. 2024;16(12):e74931.

14.

Chen

Hsu

, et al. Gastrointestinal hemorrhage in warfarin anticoagulated patients: Incidence, risk factor, management, and outcome. Biomed Res Int. 2014;2014:463767.

15.

Turcato

Bonora

Zorzi

, et al. Thirty-day mortality in atrial fibrillation patients with gastrointestinal bleeding in the emergency department: Differences between direct oral anticoagulant and warfarin users. Intern Emerg Med. 2020;15(2):311-318. doi:10.1007/s11739-019-02229-7

16.

Suh

D-C

Nelson

Choi

. Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation. Clin Ther. 2012;34(7):1569-1582. doi:10.1016/j.clinthera.2012.05.008

17.

Rikala

Kastarinen

Tiittanen

Huupponen

Korhonen

. Natural history of bleeding and characteristics of early bleeders among warfarin initiators - a cohort study in Finland. Clin Epidemiol. 2016;8:23-35.

18.

Zeng

Zhang

. Risk factors for anticoagulant-associated gastrointestinal hemorrhage: A systematic review and meta-analysis. Korean J Intern Med. 2024;39(1):77-85. doi:10.3904/kjim.2023.098

19.

Chan

Lazarus

Thadhani

Hakim

. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20(10):2223-2233. doi:10.1681/ASN.2009030319

20.

Trivedi

Yang

Szabo

. Gastrointestinal bleeding in patients on long-term dialysis. J Nephrol. 2015;28(2):235-243. doi:10.1007/s40620-014-0132-6

21.

Lin

Waters

Kwok

. Gastrointestinal bleeding in chronic kidney disease patients: A systematic review and meta-analysis. Renal Fail. 2023;45(2):2276908. doi:10.1080/0886022X.2023.2276908

22.

Protopapas

Savopoulos

Skoura

Goulis

. Anticoagulation in Patients with Liver Cirrhosis: Friend or Foe? Dig Dis Sci. 2023;68(6):2237-2246. doi:10.1007/s10620-023-07858-9

23.

Zhu

Zhou

Chen

Yan

. Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review. Am J Cardiovasc Drugs. 2020;20(2):139-147. doi:10.1007/s40256-019-00369-x

24.

Ahn

Lee

Choi

, et al. Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(11):4676-4687. doi:10.1111/bcp.15478

25.

Ray

Chung

Murray

, et al. Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding. Gastroenterology. 2016;151(6):1105-1112.e10. doi:10.1053/j.gastro.2016.08.054

26.

Lee

S-R

Kwon

Choi

E-K

, et al. Proton pump inhibitor co-therapy in patients with atrial fibrillation treated with oral anticoagulants and a prior history of upper gastrointestinal tract bleeding. Cardiovasc Drugs Ther. 2022;36(4):1-11.

27.

Tang

Sharma

Desai

, et al. A Study of Proton Pump Inhibitors and Other Risk Factors in Warfarin-Associated Gastrointestinal Bleeding. Cureus. 2021;13(1):e12624.

28.

Lurie

Loebstein

Kurnik

Almog

Halkin

. Warfarin and vitamin K intake in the era of pharmacogenetics. Br J Clin Pharmacol. 2010;70(2):164-170. doi:10.1111/j.1365-2125.2010.03672.x

29.

Leblanc

Dubé

Presse

, et al. Avoidance of Vitamin K-Rich Foods Is Common among Warfarin Users and Translates into Lower Usual Vitamin K Intakes. J Acad Nutr Diet. 2016;116(6):1000-1007. doi:10.1016/j.jand.2015.12.023

30.

Card

Hall

Watson

Kitchen

Harrington

. Portion-controlled spinach for improved vitamin K antagonist anticoagulant control. Br J Haematol. 2020;189(3):e71-ee3. doi:10.1111/bjh.16481

31.

Tan

CSS

Lee

SWH

. Warfarin and food, herbal or dietary supplement interactions: A systematic review. Br J Clin Pharmacol. 2021;87(2):352-374. doi:10.1111/bcp.14404

32.

Ghorbannezhad

Mehrabadi

Golampour-Shamkani

, et al. Genetic Determinants of Response to Statins in Cardiovascular Diseases. Curr Cardiol Rev. 2024;20(2):20-28. doi:10.2174/011573403X267793231220114042

33.

Hîncu

Apetroaei

M-M

Ștefan

, et al. Drug–Drug Interactions in Nosocomial Infections: An Updated Review for Clinicians. Pharmaceutics. 2024;16(9):1137. doi:10.3390/pharmaceutics16091137

34.

Mar

Gopinathannair

Gengler

, et al. Drug Interactions Affecting Oral Anticoagulant Use. Circ Arrhythm Electrophysiol. 2022;15(6):e007956.

35.

Sellers

Weser

. Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clin Pharmacol Ther. 1970;11(4):524-529. doi:10.1002/cpt1970114524

36.

Sharina

Sobolevsky

Papakyriakou

, et al. The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: In vitro studies. Br J Pharmacol. 2015;172(9):2316-2329. doi:10.1111/bph.13055

37.

Leonard

Brensinger

Bilker

, et al. Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. Int J Cardiol. 2017;228:761-770. doi:10.1016/j.ijcard.2016.11.245

38.

Bhagavathula

Vidyasaga

Gebreyohannes

Tesfaye

. Risk of Gastrointestinal Bleeding on Treatment With Statin Alone or With Concomitant Administration of Warfarin: A Systematic Review and Meta-analysis of 5.3 Million Participants. Ann Pharmacother. 2022;56(7):820-830. doi:10.1177/10600280211049727

39.

Pastori

Marang

Bisson

Herbert

Lip

GYH

Fauchier

. Performance of the HAS-BLED, ORBIT, and ATRIA Bleeding Risk Scores on a Cohort of 399 344 Hospitalized Patients With Atrial Fibrillation and Cancer: Data From the French National Hospital Discharge Database. J Am Heart Assoc. 2022;11(23):e026388. doi:10.1161/JAHA.121.026388

40.

Liu

Wang

Guo

. HAS-BLED vs. ORBIT scores in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis. Front Cardiovasc Med. 2023;9:1042763. doi:10.3389/fcvm.2022.1042763

41.

Wang

Zhu

Lip

GYH

Hong

. Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: A systematic review and meta-analysis. Oncotarget. 2017;8(65):109703-11. doi:10.18632/oncotarget.19858

42.

O'Brien

Simon

Thomas

, et al. The ORBIT bleeding score: A simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36(46):3258-3264.

43.

Marjani

. Genetic variations in cytochrome P450 2C9 and 2C19: A review. Curr Pharmacog Pers Med. 2017;14(1):18-28. doi:10.2174/1875692115666161214152223

44.

Presnell

Stafford

. The vitamin K-dependent carboxylase. Thromb Haemostasis. 2002;87(06):937-946. doi:10.1055/s-0037-1613115

45.

Rieder

Reiner

Gage

, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285-2293. doi:10.1056/NEJMoa044503

46.

Ageno

Gallus

Wittkowsky

Crowther

Hylek

Palareti

. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e44S-e88S. doi:10.1378/chest.11-2292

47.

Ruff

Bhatt

Steg

, et al. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol. 2014;170(3):413-418. doi:10.1016/j.ijcard.2013.11.030

48.

Marcatto

Sacilotto

Tavares

, et al. Evaluation of the Long-Term Impact on Quality After the End of Pharmacist-Driven Warfarin Therapy Management in Patients With Poor Quality of Anticoagulation Therapy. Front Pharmacol. 2020;11:1056. doi:10.3389/fphar.2020.01056

49.

Lee

Ong

Mazlan-Kepli

, et al. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol. 2021;13(9):483-492. doi:10.4330/wjc.v13.i9.483

50.

Shikdar

Vashisht

Bhattacharya

. International normalized ratio (INR). 2018.

51.

Hirsh

Fuster

Halperin

. American Heart Association/American College of Cardiology foundation guide to warfarin therapy. Circulation. 2003;107(12):1692-1711. doi:10.1161/01.CIR.0000063575.17904.4E

52.

Ansell

Hirsh

Poller

Bussey

Jacobson

Hylek

. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3):204S-233S. doi:10.1378/chest.126.3_suppl.204S

53.

Kim

Engel

, et al. Diagnosis of gastrointestinal bleeding: A practical guide for clinicians. World J Gastrointest Pathophysiol. 2014;5(4):467-478. doi:10.4291/wjgp.v5.i4.467

54.

Amin

Antunes

55.

Mujtaba

Chawla

Massaad

. Diagnosis and management of non-variceal gastrointestinal hemorrhage: A review of current guidelines and future perspectives. J Clin Med. 2020;9(2):402. doi:10.3390/jcm9020402

56.

Artigas

Martí

Soto

Esteban

Pinilla

Guillén

. Multidetector CT angiography for acute gastrointestinal bleeding: Technique and findings. Radiographics. 2013;33(5):1453-1470. doi:10.1148/rg.335125072

57.

Gralnek

Dumonceau

J-M

Kuipers

, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47(10):a1-a46. doi:10.1055/s-0034-1393172

58.

Strate

Gralnek

. ACG Clinical Guideline: Management of Patients With Acute Lower Gastrointestinal Bleeding. Am J Gastroenterol. 2016;111(4):459-474. doi:10.1038/ajg.2016.41

59.

Sadeghi

Zali

Mohaghegh Shalmani

, et al. An algorithmic approach to gastrointestinal bleeding in patients receiving antithrombotic agents. Gastroenterol Hepatol Bed Bench. 2020;13(Suppl1):S8-s17.

60.

Milling

Refaai

Sengupta

. Anticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines. Dig Dis Sci. 2021;66(11):3698-3714. doi:10.1007/s10620-020-06728-y

61.

Abraham

Barkun

Sauer

, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Off J Am Coll Gastr ACG. 2022;117(4):542-558.

62.

Abu-Sbeih

Szafron

Elkafrawy

, et al. Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy. J Gastroenterol Hepatol. 2022;37(10):1983-1990.

63.

Villa Zapata

Hansten

Panic

, et al. Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis. Thromb Haemost. 2020;120(7):1066-1074.

64.

Sung

Tsoi

Lai

Lau

. Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: A meta-analysis. Gut. 2007;56(10):1364-1373.

65.

Llach

Bordas

Salmerón

, et al. A prospective randomized trial of heater probe thermocoagulation versus injection therapy in peptic ulcer hemorrhage. Gastrointest Endosc. 1996;43(2 Pt 1):117-120.

66.

Jensen

Machicado

Hirabayashi

. Randomized controlled study of 3 different types of hemoclips for hemostasis of bleeding canine acute gastric ulcers. Gastrointest Endosc. 2006;64(5):768-773.

67.

Xavier

Campos

Robinson

Lima

EJM

da Rocha

LCM

. Endoscopic clipping for gastrointestinal bleeding: Emergency and prophylactic indications. Ann Gastroenterol. 2020;33(6):563-570.

68.

Galloro

Zullo

Luglio

, et al. Endoscopic clipping in non-variceal upper gastrointestinal bleeding treatment. Clin Endosc. 2022;55(3):339-346.

69.

Maselli

Da Rio

Manno

, et al. Efficacy of novel endoscopic hemostatic agent for bleeding control and prevention: Results from a prospective, multicenter national registry. Endosc Int Open. 2024;12(10):E1220-E12e9.

70.

Ballester

Costigan

O'Sullivan

Sengupta

McNamara

. Efficacy and applications for PuraStat(®) use in the management of unselected gastrointestinal bleeding: A retrospective observational study. World J Gastrointest Endosc. 2025;17(3):98021.

71.

Shikdar

Vashisht

Bhattacharya

72.

Van Beek

Moeyaert

Ragheb

, et al. Outcomes of Warfarin Home INR Monitoring vs Office-Based Monitoring: A Retrospective Claims-Based Analysis. J Gen Intern Med. 2024;39(7):1127-1134.

73.

Deitelzweig

Keshishian

Kang

, et al. Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients. Therap Adv Gastroenterol. 2021;14:1756284821997352.

74.

Lau

WCY

Man

KKC

, et al. Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study. Ann Intern Med. 2022;175(11):1515-1524.

75.

Tapaskar

Ham

Micic

Sengupta

. Restarting Warfarin vs Direct Oral Anticoagulants After Major Gastrointestinal Bleeding and Associated Outcomes in Atrial Fibrillation: A Cohort Study. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2022;20(2):381-9.e9.

76.

Cheng

Hua

Xiong

. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Cirrhotic Patients: A Systematic Review and Meta-Analysis. Clin Appl Thromb/Hemost: Off J Int Acad Clin Appl Thromb/Hemostasis. 2024;30:10760296241301402.

77.

Aloysius

Perisetti

Goyal

, et al. Direct-acting oral anticoagulants versus warfarin in relation to risk of gastrointestinal bleeding: A systematic review and meta-analysis of randomized controlled trials. Ann Gastroenterol. 2021;34(5):651-659.

78.

Cha

Kim

, et al. Real-World Risk of Gastrointestinal Bleeding for Direct Oral Anticoagulants and Warfarin Users: A Distributed Network Analysis Using a Common Data Model. Gut Liver. 2024;18(5):814-823.

79.

Witt

. What to do after the bleed: Resuming anticoagulation after major bleeding. Hematology Am Soc Hematol Educ Program. 2016;2016(1):620-624.

80.

Becattini

Sembolini

Paciaroni

. Resuming anticoagulant therapy after intracerebral bleeding. Vascul Pharmacol. 2016;84:15-24.

81.

Martin

Benamouzig

Gouin-Thibault

Schmidt

. Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion. Am J Cardiovasc Drugs. 2023;23(4):407-418.

82.

Slouha

Jensen

Fozo

Raj

Thomas

Gorantla

. Re-starting anticoagulation and antiplatelets after gastrointestinal bleeding: A systematic review. F1000Res. 2023;12:806.

83.

Kimmel

French

Kasner

, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283-2293.

84.

Pirmohamed

Burnside

Eriksson

, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294-2303.

85.

Johnson

Cavallari

. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25(1):33-41.

86.

Klein

Altman

Eriksson

, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-764.

87.

Yang

Chang

Savides

. New Techniques to Control Gastrointestinal Bleeding. Gastroenterol Hepatol (N Y). 2019;15(9):471-479.

88.

Lau

LHS

Sung

JJY

. Treatment of upper gastrointestinal bleeding in 2020: New techniques and outcomes. Digest Endosc: Off J Japan Gastroenterol Endosc Soc. 2021;33(1):83-94.

89.

Nagesh

Pulipaka

Bhuju

, et al. Management of gastrointestinal bleed in the intensive care setting, an updated literature review. World J Crit Care Med. 2025;14(1):101639.

90.

Cook

Griffith

Walter

, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care. 2001;5(6):368-375.